Novo Nordisk stock falls after raised forecast fails to change the debate over its obesity business
Wall Street isn't convinced the Ozempic maker has a promising path back to sustainable growth as competition from Eli Lilly intensifies.
Wall Street isn't convinced the Ozempic maker has a promising path back to sustainable growth as competition from Eli Lilly intensifies. This story matters for Finance & Markets readers tracking trade. Reported by cnbc.com. Read the full original at the source link below.
Originally reported by cnbc.com. Trade-News curates and briefs the finance & markets stories that matter. Our editorial policy →